PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand

The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical trials such as vepdegestrant (Arvinas and Pfizer), luxdegalutamide (Arvinas and Novartis), ASP3082 (Astellas Pharma), DT2216 (Dialectic Therapeutics), and others, along with increasing applicability in neurodegenerative and inflammatory diseases, are further fueling sustained R&D investment.

LAS VEGAS, Feb. 10, 2026 /PRNewswire/ — DelveInsight’s PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as HR+/HER2− Breast Cancer, Triple Negative Breast Cancer (TNBC), Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging PROTAC, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Key Takeaways from the PROTAC Market Report

The total market size of PROTAC in the leading markets is expected to surge significantly by 2034.
The report provides the total potential number of patients in the indications, such as HR+/HER2− Breast Cancer, Triple Negative Breast Cancer (TNBC), Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), and others.
Approximately 85% of patients diagnosed with metastatic breast cancer have had an early-stage breast cancer diagnosis. However, most patients with early-stage breast cancer do not go on to develop metastatic disease.
Leading PROTAC companies, such as Arvinas (NASDAQ: ARVN), Pfizer (NYSE: PFE), Novartis (SWX: NOVN), Astellas Pharma (TYO: 4503), Dialectic Therapeutics, and others, are developing novel PROTAC that can be available in the PROTAC market in the coming years.
Some of the key PROTACs in clinical trials include Vepdegestrant, Luxdegalutamide, ASP3082, DT2216, and others.

Discover PROTAC market CAGR and revenue projections @ https://www.delveinsight.com/sample-request/protac-market-forecast?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

Key Factors Driving the PROTAC Market

High Therapeutic Potential and Mechanism of Action: PROTACs offer a novel mechanism that selectively degrades disease-causing proteins rather than simply inhibiting them. This expands therapeutic possibilities, especially for targets previously considered “undruggable”, boosting industry and investor interest.
Rising Prevalence of Target Diseases: The increasing global burden of complex diseases, such as breast cancer, TNBC, mCRPC, colorectal cancer, NSCLC, and others, fuels the demand for innovative treatment options. PROTACs’ ability to target pathogenic proteins drives research and clinical investment.
Next-Generation AR Degradation in Mutant Androgen Receptor–Driven Prostate Cancer: Prostate cancer is traditionally treated with anti-androgen medications. However, PROTACs such as ARV-766 are thought to be effective in patients with AR that has mutated, particularly through a resistance mechanism such as L702H. ARV-766 has a superior and expanded efficacy profile and an improved tolerability profile compared with bavdegalutamide.
Pharmaceutical Partnerships and Licensing Landscape: Opportunities for clinical collaboration and licensing with large pharmaceutical companies are presented here. Novartis paid USD 150 million up front, primarily for the rights to Arvinas’s androgen receptor degrader ARV-766, thereby providing the company a second endorsement of its degradation strategy. It is important to note that Pfizer is already a partner with Arvinas for the PROTAC vepdegestrant.
Emerging PROTAC Drugs in Development: Some of the potential drugs in the pipeline include vepdegestrant (Arvinas and Pfizer), luxdegalutamide (Arvinas and Novartis), ASP3082 (Astellas Pharma), DT2216 (Dialectic Therapeutics), and others.

PROTAC Market Analysis

Targeted Protein Degradation (TPD) is an emerging therapeutic modality with the potential to target disease-causing proteins that have historically been difficult to reach with conventional small molecules.
PROTACs are a key class of targeted protein degradation technologies, and over the past 20 years, the concept of harnessing the ubiquitin–proteasome system has evolved from academic research into active industry-led drug development.
Nearly 90 protein degradation–based leads are currently under evaluation, with close to 20% of pipeline candidates in clinical development and the remainder in preclinical or discovery stages.
PROTACs account for more than 30% of all protein degradation pipeline drugs, underscoring their growing prominence in this therapeutic space.
The PROTAC market is expected to expand significantly in the coming years, driven by the rising number of PROTAC-designed molecules entering clinical trials, despite the absence of any approved therapies to date.
The first PROTAC molecule, ARV-110, entered clinical testing in 2019, marking a major milestone for the modality.
In 2020, early clinical data provided the first proof-of-concept for PROTACs against well-established cancer targets, including the estrogen receptor (ER) and androgen receptor (AR).
Pfizer, in collaboration with Arvinas, is currently evaluating vepdegestrant in clinical trials as both a monotherapy and in combination regimens for ER+/HER2- breast cancer and other indications.
Several major players, including Arvinas and Pfizer (Vepdegestrant), Arvinas and Novartis (Luxdegalutamide), Astellas Pharma (ASP3082), Dialectic Therapeutics (DT2216), and others, are advancing PROTAC-based therapies across multiple oncology indications such as ER+/HER2- breast cancer and metastatic prostate cancer.
Overall, PROTACs represent an exciting and rapidly maturing class of therapeutic agents, with ongoing and future studies expected to clarify their clinical role in cancer and other diseases.

Learn more about PROTACs in oncology vs other indications @ PROTAC Analysis

PROTAC Competitive Landscape

Emerging players such as Arvinas and Pfizer (Vepdegestrant), Arvinas and Novartis (Luxdegalutamide), Astellas Pharma (ASP3082), Dialectic Therapeutics (DT2216), and others are evaluating drugs in clinical trials.

Arvinas and Pfizer’s Vepdegestrant is an investigational, orally bioavailable PROTAC-based protein degrader engineered to selectively eliminate the estrogen receptor and is being developed for the treatment of ER+/HER2– breast cancer. In July 2021, Arvinas entered into a global partnership with Pfizer to jointly develop and commercialize vepdegestrant, with the two companies sharing worldwide development costs, commercialization expenses, and profits.

Arvinas and Novartis’ ARV-766 is an investigational, orally bioavailable PROTAC protein degrader designed to selectively target and degrade the androgen receptor. In preclinical studies, ARV-766 has shown activity across models expressing wild-type androgen receptor as well as tumors harboring androgen receptor mutations or amplification, key mechanisms associated with resistance to existing androgen receptor–directed therapies. ARV-766 is currently being evaluated in a Phase II clinical trial for metastatic prostate cancer. In April 2024, Arvinas entered into an exclusive global licensing agreement with Novartis for the development and commercialization of ARV-766. The transaction also included an asset purchase agreement under which Novartis acquired Arvinas’ preclinical AR-V7 program.

Astellas Pharma’s ASP3082 is a PROTAC molecule that selectively degrades the KRAS G12D protein and represents the first targeted protein degrader to advance into clinical development for this target. It has the potential to become a first-in-class therapy for solid tumors driven by KRAS G12D mutations. A Phase I clinical trial is currently ongoing in patients with KRAS G12D–mutant solid tumors, with proof-of-concept data expected in the first half of calendar year 2025. The company is preparing to advance the program into registration trials.

The anticipated launch of these emerging therapies are poised to transform the PROTAC market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the PROTAC market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about pipeline PROTAC drugs and commercial potential, visit @ PROTAC Treatment

Recent Developments in the PROTAC Market

In November 2025, Arvinas presented multiple abstracts on vepdegestrant at the San Antonio Breast Cancer Symposium (SABCS).
In October 2025, Arvinas announced new patient-reported outcomes data from the Phase III VERITAC-2 clinical trial evaluating vepdegestrant, which are being presented in a mini oral session at the 2025 European Society for Medical Oncology (ESMO) Congress.
In March 2025, Arvinas and Pfizer announced positive topline results from the Phase III VERITAC-2 trial, which met its primary endpoint in the ESR1m population, showing a significant improvement in progression-free survival (PFS) compared to fulvestrant, exceeding the pre-specified target Hazard Ratio (HR) of 0.60. However, the trial did not reach statistical significance in the intent-to-treat (ITT) population.

What are PROTACs?

PROTACs (PROteolysis TArgeting Chimeras) are an emerging class of therapeutic molecules designed to selectively degrade disease-causing proteins rather than merely inhibiting them. They are heterobifunctional compounds that simultaneously bind a target protein and an E3 ubiquitin ligase, bringing the two into close proximity and triggering ubiquitination of the target protein. This process marks the protein for destruction by the cell’s natural proteasome system. By eliminating the protein entirely, PROTACs can achieve deeper and more sustained biological effects, overcome resistance seen with traditional inhibitors, and enable targeting of previously “undruggable” proteins. As a result, PROTAC technology is gaining significant traction across oncology, immunology, and other therapeutic areas.

PROTAC Epidemiology Segmentation

The PROTAC market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020–2034 across the leading markets. The PROTAC target patient pool is segmented into:

Total Cases of Selected Indications for PROTAC
Total Eligible Patient Pool for PROTAC in Selected Indications
Total Treated Cases in Selected Indications for PROTAC

PROTAC Report Metrics	Details
Study Period	2020–2034
PROTAC Report Coverage	7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Indications Covered in the Report	HR+/HER2− Breast Cancer, Triple Negative Breast Cancer (TNBC), Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), and others
PROTAC Target Patient Pool Segmentation	Total Cases of Selected Indications for PROTAC, Total Eligible Patient Pool for PROTAC in Selected Indications, and Total Treated Cases in Selected Indications for PROTAC
Key PROTAC Companies	Arvinas (NASDAQ: ARVN), Pfizer (NYSE: PFE), Novartis (SWX: NOVN), Astellas Pharma (TYO: 4503), Dialectic Therapeutics, and others
Key PROTACs	Vepdegestrant, Luxdegalutamide, ASP3082, DT2216, and others

Scope of the PROTAC Market Report

PROTAC Therapeutic Assessment: PROTAC’ current marketed and emerging therapies
PROTAC Market Dynamics: Conjoint Analysis of Emerging PROTAC Drugs
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, PROTAC Market Access and Reimbursement

Discover emerging technologies for PROTAC design @ PROTAC Clinical Trials

Table of Contents

1	PROTAC Market Key Insights
2	PROTAC Market Report Introduction
3	Executive Summary
4	Key Events
5	Epidemiology and Market Forecast Methodology
6	PROTAC Therapies Market Overview at a Glance
6.1	Clinical Landscape (Analysis by Molecule Type, Phase, and Route of Administration [RoA])
6.2	Market Share (%) Distribution by Indications of PROTAC Therapies in 2028
6.3	Market Share (%) Distribution by Therapies of PROTAC Therapies in 2036
7	Background and Overview
8	Treatment Guidelines
9	Epidemiology and Patient Population
9.1	Key Findings
9.2	Assumptions and Rationale: 7MM
9.3	Epidemiology Scenario in the 7MM
9.3.1	Total Cases of Selected Indications for PROTACs in the 7MM
9.3.2	Total Eligible Patient Pool for PROTACs in Selected Indications in the 7MM
9.3.3	Total Treated Cases in Selected Indications for PROTACs in the 7MM
10	Emerging PROTAC Drugs
10.1	Key Cross Competition
10.2	Vepdegestrant (ARV-471): Arvinas and Pfizer
10.2.1	Product Description
10.2.2	Other Development Activities
10.2.3	Clinical Development
10.2.3.1	Clinical Trial Information
10.2.4	Safety and Efficacy
10.2.5	Analyst’s Views
10.3	Luxdegalutamide (ARV-766): Arvinas and Novartis
List to be continued…..
11	PROTAC Therapies Market: Seven Major Market Analysis
11.1	Key Findings
11.2	PROTAC Market Outlook
11.3	Conjoint Analysis
11.4	Key PROTAC Market Forecast Assumptions
11.5	Total PROTAC Market Size by Country in the 7MM
11.6	Total PROTAC Market Size by Indications in the 7MM
11.7	Total PROTAC Market Size by Therapies in the 7MM
11.8	The United States PROTAC Market Size
11.8.1	Total PROTAC Market Size by Indications in the United States
11.8.2	Total PROTAC Market Size by Therapies in the United States
11.9	EU4 and the UK PROTAC Market Size
11.1	Japan PROTAC Market Size
12	PROTAC Market Unmet Needs
13	PROTAC Market SWOT Analysis
14	KOL Views on PROTAC
15	PROTAC Market Access and Reimbursement
15.1	The United States
15.2	In EU4 and the UK
15.3	Japan
15.4	Summary and Comparison of Market Access and Pricing Policy Developments in 2025
15.5	Market Access and Reimbursement of PROTAC Therapies
16	Bibliography
17	PROTAC Market Report Methodology

Related Reports

Non-small Cell Lung Cancer Market

Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including Daiichi Sankyo, AstraZeneca, Gilead Sciences, BieGene, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda Pharmaceuticals, Eli Lilly, BerGenBio, GlaxoSmithKline, Duality Biologics, and others.

Metastatic Castration-Resistant Prostate Cancer Market

Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key mCRPC companies including Sanofi, AstraZeneca, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, among others.

Colorectal Cancer Market

Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key colorectal cancer companies, including Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris, Biotherapeutics, and others.

Metastatic HR+/HER2− Breast Cancer Market

Metastatic HR+/HER2− Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic HR+/HER2− breast cancer companies, including Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
[email protected]
+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research LLP

Source link